CORTEXYME
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
CORTEXYME
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2012-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.cortexyme.com
Total Employee:
11+
Status:
Active
Total Funding:
225 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with one approved product.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-05-10 | Novosteo | Novosteo acquired by Cortexyme | N/A |
Investors List
KG Investments
KG Investments investment in Post-IPO Equity - Cortexyme
Smallcap World Fund
Smallcap World Fund investment in Series B - Cortexyme
Vulcan Capital
Vulcan Capital investment in Series B - Cortexyme
Takeda Ventures
Takeda Ventures investment in Series B - Cortexyme
Breakout Ventures
Breakout Ventures investment in Series B - Cortexyme
Huizenga Capital Management
Huizenga Capital Management investment in Series B - Cortexyme
Dolby Family Ventures
Dolby Family Ventures investment in Series B - Cortexyme
EPIQ Capital Group
EPIQ Capital Group investment in Series B - Cortexyme
Lamond Family
Lamond Family investment in Series B - Cortexyme
Verily
Verily investment in Series B - Cortexyme
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-30 | Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary |
Official Site Inspections
http://www.cortexyme.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.92 K
- Host name: s3-website-us-west-1.amazonaws.com
- IP address: 52.219.220.147
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Cortexyme"
Quince Therapeutics - Crunchbase Company Profile & Funding
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data …See details»
Contacts, Employees, Board Members, Advisors & Alumni
Cortexyme is developing treatments for Alzheimer's and other degenerative disorders. New. …See details»
Cortexyme - Golden
Cortexyme is a biotechnology company with a focus on developing therapeutics for Alzheimer's …See details»
Quince Therapeutics - Funding, Financials, Valuation & Investors
May 10, 2022 Cortexyme is developing treatments for Alzheimer's and other degenerative …See details»
Cortexyme Completes $76 Million Series B Financing and ... - Pfizer
May 31, 2018 – Cortexyme has successfully completed key components of its phase 1 clinical …See details»
Cortexyme, Inc. | TREA
Organization. South San Francisco, CA, US Ticker Symbols. NASDAQ:CRTX. Business …See details»
Cortexyme Inc Company Profile - GlobalData
Quince Therapeutics Inc (Quince) is a clinical-stage biopharmaceutical company that focuses …See details»
Cortexyme - VentureRadar
Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration …See details»
Quince Therapeutics - Craft
Oct 29, 2024 Quince Therapeutics (formerly known as Cortexyme) is a biopharmaceutical …See details»
Cortexyme, Inc. Company Profile & Data: stocks, market cap, …
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing …See details»
Cortexyme Announces Leadership Appointments to Support …
Feb 10, 2021 “Expanding Cortexyme’s leadership team strengthens our overall operations …See details»
Cortexyme Announces Change in Executive Leadership Team
Feb 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company …See details»
Cortexyme | CRTX Stock Price, Company Overview & News - Forbes
Why Has Cortexyme’s Stock Jumped 2.5x So Far This Month Cortexyme (NASDAQ: CRTX) is …See details»
Casey Lynch Biography and Net Worth - InsiderTrades.com
Prior to co-founding Cortexyme, Ms. Lynch co-founded and led various companies and …See details»
Cortexyme Announces Clinical Hold on Atuzaginstat’s …
Jan 25, 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 26, 2022-- …See details»
Cortexyme to shift focus after FDA places hold on experimental ...
Jan 26, 2022 In November, Cortexyme said it would conduct another trial to test whether the …See details»
Cortexyme Completes $76 Million Series B - Pfizer
Cortexyme’s co-founder and chief scientific officer, Stephen Dominy, M.D. Cortexyme designed …See details»
Cortexyme drug fails in Alzheimer's trial, but company sees …
Oct 26, 2021 Cortexyme said there were "similar results" indicating a cognitive benefit to its …See details»
Cortexyme forced to pivot hopes to 2nd Alzheimer's hopeful after …
Jan 26, 2022 The FDA has stopped Cortexyme from studying its lead drug any further in …See details»
Cortexyme plans path forward for Alzheimer's drug that failed study
Nov 12, 2021 Cortexyme still needs to the meet with the FDA and other regulators to firm up …See details»